Clinical Trial

Trial Protocol ID USOR 20266_TTX-080-001

Trial Description

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Vinni Juneja, MD

Disease Types

Sponsor

  • Tizona Therapeutics, Inc.

ClinicalTrials.gov NCT ID

  • NCT04485013